Mattarollo et al. reported that etoposide, cisplatin, and doxorubicin upregulate CD95 and DR5 in various cancer cells, and that ex vivo-expanded NK cells kill sensitized targets via FasL- and TRAIL-mediated mechanisms [72]. The gene discussed is FASLG; the disease is cancer.